Gavreto (Pralsetinib) 100mg*120 | CStone China NMPA | GLT

Generic Information: Gavreto (Pralsetinib) 100mg — China-Mainland

This is the China-Mainland presentation of Gavreto, the originator pralsetinib. In China, pralsetinib is commercialized by CStone Pharmaceuticals (基石药业), which holds the exclusive Greater China development and commercialization rights under license from Blueprint Medicines, the US company that discovered the drug. The Chinese brand name is "普吉华" (Pralsetinib Capsules). Pralsetinib was the first selective RET inhibitor approved in China, and this listing is the 100 mg capsule in a 120-capsule pack.

CStone has progressively localized manufacturing of pralsetinib in China, with the NMPA approving domestic production, and the medicine has been included in China's national medical insurance scheme, meaningfully improving patient access. For cross-border buyers, the China version stands out because its reimbursed price is substantially below Western list prices.

What Is Gavreto Used For?

Gavreto treats RET fusion-positive locally advanced or metastatic non-small cell lung cancer (NSCLC), as well as RET-mutant medullary thyroid carcinoma (MTC) and RET fusion-positive thyroid cancer in adults and children aged 12 and older who require systemic therapy. These are molecularly defined cancers identified by genetic testing, and pralsetinib is a targeted therapy designed specifically for the RET-driven subset.

How Does Gavreto Work?

Pralsetinib is a potent, highly selective RET receptor tyrosine kinase inhibitor. In RET fusion-positive or RET-mutant tumours, the RET pathway is constitutively active and drives cancer cell growth. By blocking RET and its downstream signalling, Gavreto interrupts this growth signal. Its selectivity for RET — including secondary resistance mutations — distinguishes it from older multi-kinase inhibitors and supports its oral, once-daily dosing.

Indications

• Locally advanced or metastatic RET fusion-positive non-small cell lung cancer (NSCLC) in adults.
• Advanced or metastatic RET-mutant medullary thyroid carcinoma (MTC) in adults and children 12 years and older requiring systemic therapy.
• Advanced or metastatic RET fusion-positive thyroid cancer in adults and children 12 years and older requiring systemic therapy.

Dosage and Administration

The recommended dose is 400 mg once daily, taken as four 100 mg capsules on an empty stomach — no food for at least 2 hours before and 1 hour after dosing. A 120-capsule pack provides 30 days of therapy. Dosing may be adjusted for adverse reactions, and blood pressure, liver function and blood counts are monitored during treatment.

Side Effects

Common adverse reactions include fatigue, constipation, musculoskeletal pain, hypertension, diarrhoea and elevated liver enzymes. Interstitial lung disease/pneumonitis is a serious risk that requires prompt reporting of respiratory symptoms. Blood pressure should be managed before and during therapy, and patients should report any unusual bleeding or visual changes.

Storage

Store below 30°C in the original package, away from moisture and out of the reach of children. Use before the expiry date printed on the pack.

Why Choose the China Version of Gavreto?

The China-Mainland Gavreto is priced substantially below the US list price of the same medicine — roughly half or lower — because it is nationally reimbursed in China. This makes it one of the more economical ways to access originator pralsetinib. GLT documents each batch and guides international buyers through the export and import requirements for sourcing the China presentation, making it a meaningful cost-saving route without switching to a generic.

How to Order Gavreto (China) from GLT

To order the China-Mainland Gavreto 100 mg (120 capsules), message GLT on WhatsApp at +86 15234153837 or email [email protected]. State your quantity, destination and order type, and we confirm the current China price, batch origin and required documentation before dispatch.

FAQ

Who commercializes Gavreto in China? CStone Pharmaceuticals (基石药业) commercializes pralsetinib (普吉华/Gavreto) in Greater China under license from Blueprint Medicines, which discovered the drug.

Is Gavreto reimbursed in China? Yes, pralsetinib is included in China's national medical insurance scheme, making the China presentation notably affordable.

Why is the China version cheaper? China's national reimbursement and localized manufacturing have brought the cost of pralsetinib well below Western list prices, so the China presentation is an economical originator option.